Top Qs
Timeline
Chat
Perspective
Bimekizumab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Bimekizumab, sold under the brand name Bimzelx (/bɪmˈzɛlɪks/ bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.[6]
The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6] Injection site reactions were also common, reported in 3% of subjects.[8]
Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.[11][12]
In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.[13]
Remove ads
Medical uses
In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]
Society and culture
Names
Bimekizumab is the international nonproprietary name (INN).[14]
Research
Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[15] but also secukinumab[16] and ustekinumab[17] for the treatment of plaque psoriasis.
The approval for the treatment of active moderate-to-severe hidradenitis suppurativa (HS) in adults was supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS.[18][19][20]
References
Further reading
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads